2. Search Result
Search Result
Results for "

H69

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19137
    Pibrozelesin

    KW 2189 free base

    		 Antibiotic Infection Cancer
    Pibrozelesin (KW 2189 free base) is the derivative of antibiotic Duocarmycin B2. Pibrozelesin exhibits antitumor activity, inhibits proliferation of cell H69 with an IC50 of 1.9 μM. Pibrozelesin induces the DNA strand breaks upon activation via carboxyl esterase .
    Pibrozelesin
  • HY-118899
    XR5944

    		Others Cancer
    XR5944 is an anti-tumor compound with DNA-targeting activity. As a topoisomerase inhibitor, XR5944 can effectively inhibit the activities of topoisomerase I and II. XR5944 shows excellent anti-tumor activity against human and mouse tumor cells in vitro and in vivo. XR5944 exhibits significant potency in multiple cell lines, with IC50 values of 0.04-0.4 nM. XR5944 is not affected by atypical drug resistance in cells and remains significantly active even in cells overexpressing P-glycoprotein or multidrug resistance-related proteins. XR5944 showed anti-tumor efficacy in human tumor models of H69 small cell lung cancer and HT29 colon cancer, inducing tumor regression in most animals in the HT29 model. XR5944 can be used to study biological processes related to colon and lung cancer .
    XR5944
  • HY-159096
    Apoptosis inducer 21

    		Apoptosis Cancer
    Apoptosis inducer 21 (Compound 5h) inhibits the proliferation of lung cancer cell H69AR with an IC50 of 1.58 μM. Apoptosis inducer 21 arrests the cell cycle at G0/G1 phase, induces apoptosis in H69AR .
    Apoptosis inducer 21
  • HY-163632
    EGFR-IN-112

    		EGFR Cancer
    EGFR-IN-112 (SPP10) is an EGFR kinase inhibitor which exhibits IC50s of 2.31 ± 0.3, 3.16 ± 0.8, and 4.2 ± 0.2 μM, against MCF-7, H69AR, and PC-3 cancer cells, respectively. EGFR-IN-112 also demonstrates selective cytotoxicity against cancer cells .
    EGFR-IN-112
  • HY-148837
    c-Myc inhibitor 7

    		PROTACs c-Myc Casein Kinase Infection Cardiovascular Disease Cancer
    c-Myc inhibitor 7 is a c-Myc inhibitor and a multiple target protein degrader (PROTAC). c-Myc inhibitor 7 effective degrades c-MYC, CK1α, GSPT1 and IKZF1/2/3 proteins in a variety of tumor cells. c-Myc inhibitor 7 can be used for c-Myc high expression related disease research, such as cancer, cardiovascular and cerebrovascular diseases, and viral infection (Pink: c-Myc ligand (HY-168685); Blue: E3 ligase ligand (HY-W093472); Black: linker (HY-W015808)) .
    c-Myc inhibitor 7
  • HY-120436
    RM 49

    		Others Cancer
    RM 49 is the derivative of Mitomycin C (HY-13316). RM 49 exhibits cytotoxicity in SCLC and NSCLC lung cancer cells with IC50 of 0.01-0.5 μg/mL. RM 49 exhibits high relative antitumor activity in compared with Mitomycin C, Cisplatin (HY-17394), Carboplatin (HY-17393) and Doxorubicin (HY-15142) .
    RM 49

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: